Histidine-rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease

Hepatology

Volumn 63, Issue 4, 2016, Pages 1310-1324

  Bartneck, Matthias ^a   Fech, Viktor ^a   Ehling, Josef ^a   Govaere, Olivier ^b   Warzecha, Klaudia Theresa ^a   Hittatiya, Kanishka ^c   Vucur, Mihael ^a   Gautheron, Jérémie ^a   Luedde, Tom ^a   Trautwein, Christian ^a   Lammers, Twan ^a,d,e   Roskams, Tania ^b   Jahnen Dechent, Willi ^f   Tacke, Frank ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF TWENTE   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

^f RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALGRANULIN B; CD163 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CXCL9 CHEMOKINE; GAMMA INTERFERON; GLYCOPROTEIN; HISTIDINE RICH GLYCOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 6; MACROPHAGE DERIVED CHEMOKINE; MANNOSE RECEPTOR C TYPE 1; PROSTAGLANDIN F; UNCLASSIFIED DRUG; VASCULOTROPIN; BIOLOGICAL MARKER; HISTIDINE-RICH PROTEINS; PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CARBON TETRACHLORIDE-INDUCED LIVER FIBROSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC HEPATITIS; CHRONIC HEPATITIS C; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DOWN REGULATION; EXPERIMENTAL LIVER INJURY; EXPERIMENTAL STEATOHEPATITIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER HISTOLOGY; LIVER PROTECTION; MACROPHAGE ACTIVATION; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; C57BL MOUSE; CELL CULTURE; COMPARATIVE STUDY; DISEASE MODEL; FATTY LIVER; HEPATITIS C; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; METABOLISM; NEEDLE BIOPSY; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; RANDOMIZATION; RISK ASSESSMENT;

ANIMALS; BIOMARKERS; BIOPSY, NEEDLE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FATTY LIVER; HEPATITIS C; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MACROPHAGE ACTIVATION; MICE; MICE, INBRED C57BL; PROGNOSIS; PROTEINS; RANDOM ALLOCATION; RISK ASSESSMENT;

EID: 84975743970     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28418     Document Type: Article

References (36)

1. Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest 2013;123:1887-1901.
2. Heymann F, Trautwein C, Tacke F. Monocytes and macrophages as cellular targets in liver fibrosis. Inflamm Allergy Drug Targets 2009;8:307-318.
3. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22:231-237.
4. Ramachandran P, Pellicoro A, Vernon MA, Boulter L, Aucott RL, Ali A, et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci U S A 2012;109:E3186-E3195.
5. Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis. J Hepatol 2014;60:1090-1096.
6. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008;13:453-461.
7. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131:463-475.
8. He C, Ryan AJ, Murthy S, Carter AB. Accelerated development of pulmonary fibrosis via Cu, Zn-SOD-induced alternative activation of macrophages. J Biol Chem 2013;288:20745-20757.
9. Meznarich J, Malchodi L, Helterline D, Ramsey SA, Bertko K, Plummer T, et al. Urokinase plasminogen activator induces pro-fibrotic/m2 phenotype in murine cardiac macrophages. PLoS One 2013;8:e57837.
10. Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 2014;40:274-288.
11. Wan J, Benkdane M, Teixeira-Clerc F, Bonnafous S, Louvet A, Lafdil F, et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 2014;59:130-142.
12. Wan J, Benkdane M, Alons E, Lotersztajn S, Pavoine C. M2 kupffer cells promote hepatocyte senescence: an IL-6-dependent protective mechanism against alcoholic liver disease. Am J Pathol 2014;184:1763-1772.
13. Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, Merad M, et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 2014;159:1312-1326.
14. Hulett MD, Parish CR. Murine histidine-rich glycoprotein: cloning, characterization and cellular origin. Immunol Cell Biol 2000;78:280-287.
15. Leung LL. Interaction of histidine-rich glycoprotein with fibrinogen and fibrin. J Clin Invest 1986;77:1305-1311.
16. Blank M, Shoenfeld Y. Histidine-rich glycoprotein modulation of immune/autoimmune, vascular, and coagulation systems. Clin Rev Allergy Immunol 2008;34:307-312.
17. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011;19:31-44.
18. Tugues S, Honjo S, Konig C, Noguer O, Hedlund M, Botling J, et al. Genetic deficiency in plasma protein HRG enhances tumor growth and metastasis by exacerbating immune escape and vessel abnormalization. Cancer Res 2012;72:1953-1963.
19. Tsuchida-Straeten N, Ensslen S, Schafer C, Woltje M, Denecke B, Moser M, et al. Enhanced blood coagulation and fibrinolysis in mice lacking histidine-rich glycoprotein (HRG). J Thromb Haemost 2005;3:865-872.
20. Hammerich L, Bangen JM, Govaere O, Zimmermann HW, Gassler N, Huss S, et al. Chemokine receptor CCR6-dependent accumulation of gammadelta T cells in injured liver restricts hepatic inflammation and fibrosis. Hepatology 2014;59:630-642.
21. Karlmark KR, Zimmermann HW, Roderburg C, Gassler N, Wasmuth HE, Luedde T, et al. The fractalkine receptor CX(3)CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology 2010;52:1769-1782.
22. Bartneck M, Ritz T, Keul HA, Wambach M, Bornemann J, Gbureck U, et al. Peptide-functionalized gold nanorods increase liver injury in hepatitis. ACS Nano 2012;6:8767-8777.
23. Baeck C, Wehr A, Karlmark KR, Heymann F, Vucur M, Gassler N, et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 2012;61:416-426.
24. Gremse F, Grouls C, Palmowski M, Lammers T, de Vries A, Grull H, et al. Virtual elastic sphere processing enables reproducible quantification of vessel stenosis at CT and MR angiography. Radiology 2011;260:709-717.
25. Ehling J, Theek B, Gremse F, Baetke S, Mockel D, Maynard J, et al. Micro-CT imaging of tumor angiogenesis: quantitative measures describing micromorphology and vascularization. Am J Pathol 2014;184:431-441.
26. Baker M, Robinson SD, Lechertier T, Barber PR, Tavora B, D'Amico G, et al. Use of the mouse aortic ring assay to study angiogenesis. Nat Protoc 2012;7:89-104.
27. Ehling J, Bartneck M, Wei X, Gremse F, Fech V, Mockel D, et al. CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut 2014;63:1960-1971.
28. Odink K, Cerletti N, Bruggen J, Clerc RG, Tarcsay L, Zwadlo G, et al. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 1987;330:80-82.
29. Hogger P, Erpenstein U, Rohdewald P, Sorg C. Biochemical characterization of a glucocorticoid-induced membrane protein (RM3/1) in human monocytes and its application as model system for ranking glucocorticoid potency. Pharm Res 1998;15:296-302.
30. Gonzalez-Teran B, Cortes JR, Manieri E, Matesanz N, Verdugo A, Rodriguez ME, et al. Eukaryotic elongation factor 2 controls TNF-alpha translation in LPS-induced hepatitis. J Clin Invest 2013;123:164-178.
31. Xu J, Chi F, Guo T, Punj V, Lee WN, French SW, Tsukamoto H. NOTCH reprograms mitochondrial metabolism for proinflammatory macrophage activation. J Clin Invest 2015;125:1579-1590.
32. Gram J, Jespersen J, Ingeberg S, Bentsen KD, Bach E. Plasma histidine-rich glycoprotein and plasminogen in patients with liver disease. Thromb Res 1985;39:411-417.
33. Saito H, Goodnough LT, Boyle JM, Heimburger N. Reduced histidine-rich glycoprotein levels in plasma of patients with advanced liver cirrhosis. Possible implications for enhanced fibrinolysis. Am J Med 1982;73:179-182.
34. Leebeek FW, Kluft C, Knot EA, De Maat MP. Histidine-rich glycoprotein is elevated in mild liver cirrhosis and decreased in moderate and severe liver cirrhosis. J Lab Clin Med 1989;113:493-497.
35. Mossanen JC, Tacke F. Role of lymphocytes in liver cancer. Oncoimmunology 2013;2:e26468.
36. Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, Van Vlierberghe H. Angiogenesis in chronic liver disease and its complications. Liver Int 2011;31:146-162.